Trials / Unknown
UnknownNCT05995093
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 462 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 94 Years
- Healthy volunteers
- Not accepted
Summary
The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.
Detailed description
Disseminated intravascular coagulation (DIC) is a life-threatening condition with high mortality, necessitating timely and accurate diagnosis for effective management. However, current diagnostic systems can not recognize DIC at its reversible phase, causing suboptimal treatment outcomes. Consequently, the current diagnostic criteria for DIC lacks earlier laboratory indicators. Therefore, the investigators aimed to assess the diagnostic potential of selected hemostatic biomarkers, including thrombin-antithrombin complex (TAT), soluble thrombomodulin (sTM), tissue plasminogen activator inhibitor complex (tPAI-C), α2-plasmin inhibitor plasmin complex (PIC) and anti-thrombin III (ATIII), in evaluating DIC, allowing for proactive diagnosis before the disease progresses into its irreversible phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | no intervention |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
- First posted
- 2023-08-16
- Last updated
- 2023-10-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05995093. Inclusion in this directory is not an endorsement.